574 reports of this reaction
2.5% of all DURVALUMAB reports
#5 most reported adverse reaction
PYREXIA is the #5 most commonly reported adverse reaction for DURVALUMAB, manufactured by AstraZeneca Pharmaceuticals LP. There are 574 FDA adverse event reports linking DURVALUMAB to PYREXIA. This represents approximately 2.5% of all 23,251 adverse event reports for this drug.
Patients taking DURVALUMAB who experience pyrexia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PYREXIA is a less commonly reported adverse event for DURVALUMAB, but still significant enough to appear in the safety profile.
In addition to pyrexia, the following adverse reactions have been reported for DURVALUMAB:
The following drugs have also been linked to pyrexia in FDA adverse event reports:
PYREXIA has been reported as an adverse event in 574 FDA reports for DURVALUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
PYREXIA accounts for approximately 2.5% of all adverse event reports for DURVALUMAB, making it a notable side effect.
If you experience pyrexia while taking DURVALUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.